Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen 518060, China.
Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen 518060, China.
Bioorg Chem. 2024 Oct;151:107690. doi: 10.1016/j.bioorg.2024.107690. Epub 2024 Aug 2.
c-MYC is one of the most important oncogenes, which is overexpressed in many cancers, and is highly related to development, metastasis, and drug resistance of cancers. The G4 structure in the promoter of c-MYC oncogene contributes a lot to the gene transcriptional mechanism. Small-molecule ligands binding to the c-MYC G4 appear to be a new class of anticancer agents. However, selective ligands for the c-MYC G4 over other G4s have been rarely reported. In this study, we reported a novel fluorescent ligand by migrating the benzene group on a carbazole-benzothiazolium scaffold, which was demonstrated to exhibit considerable specificity to the c-MYC G4, which was distinguished from other small-molecule ligands. The further cellular experiments suggested that this ligand may indeed target the promoter G4 and cause apparent transcriptional inhibition of the c-MYC oncogene instead of other G4-mediated oncogenes, which thereby resulted in cancer cell growth inhibition. Collectively, this study provided a good example for developing specific c-MYC G4 ligands, which may further develop into an effective anticancer agent that inhibit the c-MYC expression.
c-MYC 是最重要的癌基因之一,在许多癌症中过表达,与癌症的发展、转移和耐药性密切相关。c-MYC 癌基因启动子中的 G4 结构对基因转录机制有很大贡献。与 c-MYC G4 结合的小分子配体似乎是一类新的抗癌药物。然而,选择性配体用于 c-MYC G4 而不是其他 G4 的报道很少。在这项研究中,我们通过将苯环迁移到咔唑-苯并噻唑骨架上,报道了一种新型荧光配体,该配体被证明对 c-MYC G4 具有相当的特异性,与其他小分子配体区分开来。进一步的细胞实验表明,该配体可能确实靶向启动子 G4,并导致 c-MYC 癌基因的明显转录抑制,而不是其他 G4 介导的癌基因,从而导致癌细胞生长抑制。总之,本研究为开发特异性 c-MYC G4 配体提供了一个很好的范例,可能进一步开发成一种有效的抗癌药物,抑制 c-MYC 的表达。